Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

undefined; Stefano Di Donato; Marie‐Elise Truchetet; Marco Minerba; Oliver Distler; Juan José Alegre Sancho; Yolanda Braun‐Moscovici; Christina Bergmann; Petros Sfikakis; Jeska K de Vries‐Bouwstra; Murray Baron; Silvia Bellando‐Randone; Lorenzo Dagna; Christopher P Denton; Madelon C Vonk; Vanessa Smith; Ivan Castellvi; Gabriela Riemekasten; Andra Balanescu; Masataka Kuwana; Maria De Santis; Kamal Solanki; Anastas Batalov; Vahan Mukuchyan; Marco Matucci‐Cerinic; Yannick Allanore; Francesco Del Galdo; Michael Hughes

Journal ArticleOPEN ACCESS

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

Di Donato S
Truchetet M
et al.

Arthritis Care & Research (2026)

DOI: 10.1002/acr.80100

0Citations

1Readers

Cite

CITATION STYLE

APA

Di Donato, S., Truchetet, M., Minerba, M., Distler, O., Alegre Sancho, J. J., … Hughes, M. (2026). Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort. Arthritis Care & Research. https://doi.org/10.1002/acr.80100

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

Cite

Register to see more suggestions